Liu J.,Chaoyan Sanhuan Cancer Hospital |
Cui C.,Cancer Hospital and Institute |
Wang J.,Cancer Hospital and Institute |
Zhang Y.,Chaoyan Sanhuan Cancer Hospital |
And 7 more authors.
Chinese Journal of Clinical Oncology
Objective: This study aims to determine the efficacy of chemotherapy and to identify potential chemotherapy agents for advanced primary duodenal carcinoma (PDC). Methods: Fifty-six patients with advanced PDC, who did and did not receive chemotherapy, were involved in this study. Response rates (RR), disease control rates (DCR), progression-free survival (PFS), and overall survival (OS) were analyzed. Results: The overall RR and DCR of 43 patients were 19.04% and 71.42%, respectively. The patients who received chemotherapy agents fluorourzcil and oxaliplatin exhibited higher RR compared with patients who received other chemotherapy combinations (35.29% vs. 7.69%, P=0.010 9). Palliative chemotherapy improved the OS of patients with advanced PDC compared with patients who did not receive chemotherapy (13.35 months vs. 5.65 months, HR=0.203, 95% CI: 0.083 to 0.497, P=0.000 5). Compared with the use of other chemotherapy regimens, treatment with a fluorourzcil-based chemotherapy agent resulted in a longer PFS (5.08 months vs. 1.08 months, HR=0.004, 95% CI:0.000 to 0.315, P=0.013 2). Multivariate analysis indicated mucinous histology and lymph mode metastasis as factors predictive of poor prognosis in patients with advanced PDC. Conclusion: Palliative chemotherapy may improve the OS of patients with advanced PDC. Source
Liu J.,Chaoyang Sanhuan Cancer Hospital |
Zhang Y.,Chaoyang Sanhuan Cancer Hospital |
Qu T.,Cancer Hospital and Institute |
Shi S.,Chaoyang Sanhuan Cancer Hospital |
And 7 more authors.
Chinese Journal of Clinical Oncology
Objective: This retrospective study aims to determine the efficacy of chemotherapy and improve a salvage chemotherapy agent for metastatic colorectal cancer (MCRC) after failure of treatment with irinotecan and oxaliplatin. Methods: Between January 2002 and March 2013, 37 patients with metastatic MCRC who had progressed after treatment with irinotecan and oxaliplatin were analyzed for their response rate (RR) and progression-free survival (PFS). Results: The overall RR of the 37 patients was 13.51%, with 5 cases of partial response (PR), 12 cases of disease stabilization (SD), and 20 cases of progression (PD). Compared with other chemotherapy regimens, treatment with a pemetrexed-based chemotherapy agent had a higher RR (17.64% vs. 10.00%, P=0.64) without a longer PFS (2.00 months vs. 1.63 months, HR=0.79, 95%, CI: 0.35 to 1.78, P=0.58). Compared with other chemotherapy regimens, treatment with a raltirexed-based chemotherapy agent had a higher RR (16.67% vs. 12.00%, P=0.34) without a longer PFS (1.58 months vs. 1.90 months, HR=2.24, 95%, CI: 0.98 to 5.12, P=0.06).Conclusion: In patients with MCRC after failure of treatment with irinotecan and oxaliplatin, a pemetrexed-based or raltirexed-based chemotherapy agent may beneficial during salvage treatment and is therefore worthy of further study. Source
Zhou Z.-G.,Xidian University |
Liu F.,Xidian University |
Jiao L.-C.,Xidian University |
Wang Z.-L.,Cancer Hospital and Institute |
And 3 more authors.
BMC Medical Informatics and Decision Making
Background: Lymph node metastasis (LNM) in gastric cancer is a very important prognostic factor affecting long-term survival. Currently, several common imaging techniques are used to evaluate the lymph node status. However, they are incapable of achieving both high sensitivity and specificity simultaneously. In order to deal with this complex issue, a new evidential reasoning (ER) based model is proposed to support diagnosis of LNM in gastric cancer. Methods. There are 175 consecutive patients who went through multidetector computed tomography (MDCT) consecutively before the surgery. Eight indicators, which are serosal invasion, tumor classification, tumor enhancement pattern, tumor thickness, number of lymph nodes, maximum lymph node size, lymph node station and lymph node enhancement are utilized to evaluate the tumor and lymph node through CT images. All of the above indicators reflect the biological behavior of gastric cancer. An ER based model is constructed by taking the above indicators as input index. The output index determines whether LNM occurs for the patients, which is decided by the surgery and histopathology. A technique called k-fold cross-validation is used for training and testing the new model. The diagnostic capability of LNM is evaluated by receiver operating characteristic (ROC) curves. A Radiologist classifies LNM by adopting lymph node size for comparison. Results: 134 out of 175 cases are cases of LNM, and the remains are not. Eight indicators have statistically significant difference between the positive and negative groups. The sensitivity, specificity and AUC of the ER based model are 88.41%, 77.57% and 0.813, respectively. However, for the radiologist evaluating LNM by maximum lymph node size, the corresponding values are only 63.4%, 75.6% and 0.757. Therefore, the proposed model can obtain better performance than the radiologist. Besides, the proposed model also outperforms other machine learning methods. Conclusions: According to the biological behavior information of gastric cancer, the ER based model can diagnose LNM effectively and preoperatively. © 2013 Zhou et al.; licensee BioMed Central Ltd. Source
Tian C.,Cancer Hospital and Institute |
Zhang L.,Cancer Hospital and Institute |
Hu D.,Fenjinting Hospital |
Ji J.,Cancer Hospital and Institute
Molecular and Cellular Biochemistry
This study aims to investigate the roles of ghrelin signaling in human gastric carcinoma cell lines AGS and SGC7901. Effects of ghrelin signaling on CDK6, P53, NF-κB/P65 and MMP2 mRNA and/or protein expression were determined by real-time PCR and western blot. MTT method and flow cytometry were performed to assess the gastric cancer cell proliferation. The SGC7901 cells overexpressing ghrelin were inoculated into nude mice to produce tumors which were measured later. The wound-healing assay and cell invasion assay were used to test the cell migration and invasive ability of gastric cancer. Ghrelin signaling promotes the oncogene CDK6 gene expression and represses the tumor suppressor gene P53 gene expression in gastric cancer. Ghrelin activates NF-κB/P65 signaling pathway through GHS-R in gastric cancer. Ghrelin upregulates the metastasis factor MMP2 expression via GHS-R/NF-κB signaling pathway in gastric cancer cells and promotes tumor cells migration and invasion, suggesting that ghrelin signaling is a critical pathway in cancer metastasis. Ghrelin induces cell proliferation, migration and invasion via GHS-R/NF-κB signaling pathway in gastric cancer cells. Ghrelin treatment must be avoided for gastric cancer patients. © 2013 Springer Science+Business Media New York. Source
Xue Y.,Beijing University of Technology |
Xue Y.,Cancer Hospital and Institute |
Wu L.,Peking University |
Liu Y.,Cancer Hospital and Institute |
And 5 more authors.
This study is to investigate the relationship between ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) expression and lung cancer clinicopathological factors, and the impact of ENTPD5 on lung cancer cell functions. Lung cancer specimens and matched adjacent normal tissues were obtained from patients without any preoperative radiotherapy or chemotherapy. Knockdown of ETNPD5 expression led to significantly decreased lung cancer cell growth rate, markedly increased apoptosis and the ability to repair, and significantly reduced invasion. Gene chip tests showed that knockdown of ENTPD5 expression caused more Caspase expression. Quantitative real-time polymerase chain reaction showed that the Caspase 3 expression was significantly increased after the knockdown of ENTPD5. In addition, immunohistochemistry showed that the tumor growth marker, proliferating cell nuclear antigen, was significantly reduced in the knockdown model. Tumorigenicity assay and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay showed that the apoptosis of lung cancer cells was increased in the knockdown model. Our results suggest that ENTPD5 affects lung cancer apoptosis via Caspase 3 pathway, and can be potentially used to monitor prognosis or to guide appropriate therapeutic regimens. © 2015 Xue et al. Source